Exosomal nanocarriers of immune fate: molecular insights into cancer immunity, pathogen defense, and emerging immunotherapies
Clinical and Experimental Immunology · 2026
DOI: 10.1093/cei/uxag009 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Experimental Immunology, 2026. Verfasst von Kamoru A Adedokun und 4 weiteren Autor:innen. Beteiligte Einrichtung: Immunology Department, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA. Hauptthemen laut MEDLINE: Exosomes, Neoplasms, Immunotherapy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 148 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Exosomes, the nanoscale extracellular vesicles released by most cell types, are increasingly recognized as potent regulators of immune communication. This review provides a mechanistic and integrative perspective on the immunological functions of exosomes, highlighting their roles in both immune stimulation and suppression across physiological and pathological contexts. We begin by dissecting the molecular architecture of exosomes—focusing on immunologically active components such as ESCRT proteins, tetraspanins, RabGTPases, and lipid mediators—and explore how these elements contribute to exosome biogenesis and immune function. The review further examines exosomal cargo enriched in pattern recognition receptor (PRR) ligands, including damage-associated molecular patterns (DAMPs), pathogen-associated molecular patterns (PAMPs), and microRNAs, and discusses how these molecules activate toll-like receptors and other PRRs to orchestrate innate immune responses through endosomal and cytosolic signaling cascades. Special emphasis is given to MHC-mediated antigen presentation via exosomes, distinguishing classical and non-canonical pathways and their interplay with downstream immune signaling mechanisms. We present a dichotomous view of exosomes as both immunostimulatory and immunosuppressive agents, detailing their roles in T-cell cross-priming, dendritic cell maturation, tumor progression, and metastasis. Moreover, we review pathogen-driven hijacking of exosomal pathways and their implications for immune evasion. Finally, we discuss the therapeutic promise of exosomes in cancer immunotherapy and vaccine design, advocating for their strategic integration into next-generation immunomodulatory approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Immunology Department, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
- School of Biosciences, Faculty of Health and Medical Sciences, Taylor's University, Subang Jaya, Selangor 47500, Malaysia.
- Medical Laboratory Science Department, University of Ilorin, Ilorin, Nigeria.
- Zoology Department, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia.
- NMC Healthcare, Medical Record and Clinical Documentation Unit, Abu Dhabi 764659, UAE.
ORCID-Profile: Kamoru A Adedokun, Aminah Bello, Gbadebo M Oyeniyi, Musa K Oladejo, Tajudeen A Adebisi
Zitieren
APA
Adedokun, K. A., Bello, A., Oyeniyi, G. M., Oladejo, M. K., & Adebisi, T. A. (2026). Exosomal nanocarriers of immune fate: molecular insights into cancer immunity, pathogen defense, and emerging immunotherapies. Clinical and Experimental Immunology. https://doi.org/10.1093/cei/uxag009
Vancouver
Adedokun KA, Bello A, Oyeniyi GM, Oladejo MK, Adebisi TA. Exosomal nanocarriers of immune fate: molecular insights into cancer immunity, pathogen defense, and emerging immunotherapies. Clinical and Experimental Immunology. 2026. doi:10.1093/cei/uxag009
BibTeX
@article{Adedokun2026,
author = {Adedokun, Kamoru A and Bello, Aminah and Oyeniyi, Gbadebo M and Oladejo, Musa K and Adebisi, Tajudeen A},
title = {Exosomal nanocarriers of immune fate: molecular insights into cancer immunity, pathogen defense, and emerging immunotherapies},
journal = {Clinical and Experimental Immunology},
year = {2026},
doi = {10.1093/cei/uxag009}
}
EUVIMED